Feature | Lung Cancer | June 24, 2015

CT Allows Nonsurgical Management of Some Lung Nodules

Mount Sinai study concludes detection of non-solid, cancerous nodules possible in 12-month intervals

low-dose CT, LDCT, lung cancer, screening, nonsolid nodules, Mount Sinai

June 24, 2015 - People who have nonsolid lung nodules can be safely monitored with annual low-dose computed tomography (CT) screening, according to a new study published online in the journal Radiology. Researchers said the findings could help spare patients from unnecessary surgery and additional imaging.

Lung nodules are small masses of tissue in the lungs that can be benign or cancerous. They are classified as solid, part solid or nonsolid, based on their appearance on CT. In nonsolid lung nodules, normal lung tissue is visible through the nodule. Nonsolid nodules are visible on CT scans of the chest, and management of them is challenging.

"Nonsolid nodules could be due to inflammation, infection or fibrosis, but could also be cancerous or a precursor of cancer," said study co-author Claudia I. Henschke, Ph.D., M.D., from the Department of Radiology at Mount Sinai School of Medicine in New York City. "For screening, we have to define which nodules need further workup and how quickly we have to do that workup."

In the new study, Henschke and colleagues analyzed results from 57,496 participants in the International Early Lung Cancer Program (I-ELCAP), a major worldwide initiative focused on reducing deaths from lung cancer. The patients underwent baseline and annual repeat screenings, and the researchers evaluated the prevalence of nonsolid nodules and their effect on long-term outcomes.

A nonsolid nodule was identified in 2,392 (4.2 percent) of the baseline screenings, and further analysis led to the diagnosis of 73 cases of cancer. A new nonsolid nodule was identified in 485 of 64,677 annual repeat screenings, or 0.7 percent, and 11 were diagnosed with Stage I cancer. Surgery was 100 percent curative in all cases, with a median follow-up since diagnosis of more than six years.

The nonsolid nodule developed a solid component-a warning sign of invasive cancer-in 22 cases prior to treatment. However, the median transition time from nonsolid to part-solid was more than two years. No cancers occurred in new nodules 15 millimeters or larger in diameter.

The findings suggest that nonsolid nodules of any size can be safely followed with low-dose CT at 12-month intervals to assess a potential transition to part-solid.

"The results show that if we see a nonsolid lung nodule of any size, we can tell people to come back in one year for another CT," Henschke said. "These findings are important for reducing unnecessary CT scans and possible biopsies or surgery in programs of CT screening for lung cancer."

One immediate benefit may be a reduction in the overtreatment of nodules, according to study co-author David F. Yankelevitz, M.D., from Mount Sinai.

"Many recommendations had been fairly aggressive with respect to nonsolid nodules," Dr. Yankelevitz said. "These results show that there is no reason to be aggressive in pursuit of cancer, so long as the nodules stay in this nonsolid form."

The study results also provide additional information to help in the shared decision-making process between physician and patient, Yankelevitz said. Patients can be assured that one-year low-dose CT screening intervals are sufficient, and also know that more aggressive treatment may be required if the nodules develop solid components.

"This is a major step forward for lung cancer screening protocols," Yankelevitz said. "It will help us cut down on the number of surgeries and unnecessary imaging tests."

For more information: www.radiology.org

Related Content

This image, taken with Canon's Aquilion One, shows a lung with metastases from bowel cancer.

This image, taken with Canon’s Aquilion One, shows a lung with metastases from bowel cancer. Image courtesy of Canon.

Feature | Lung Cancer | April 18, 2018 | Jeff Zagoudis
In recent years, low-dose computed tomography (CT) screening has emerged as a proven, effective method to detect lung
FDA Clears Siemens' Somatom go.All, go.Top CT Scanners
Technology | Computed Tomography (CT) | April 18, 2018
The U.S. Food and Drug Administration (FDA) has cleared the Somatom go.All and Somatom go.Top computed tomography (CT)...
Chest X-ray AI Algorithm Correctly Identifies Lung Disease for Dubai Health Authority
Feature | Artificial Intelligence | April 17, 2018
The Dubai Health Authority (DHA) announced the preliminary results of a chest X-ray artificial intelligence (AI)...
Canon Medical Systems' Aquilion Precision CT Receives FDA Clearance
Technology | Computed Tomography (CT) | April 13, 2018
April 13, 2018 — Canon Medical Systems USA Inc. this week received U.S.
Healthcare Administrative Partners Launches Deep Dive Analytics Service
Technology | Analytics Software | April 12, 2018
Healthcare Administrative Partners (HAP) announced the launch of Deep Dive Analytics, an integrated clinical data...
First Patient Treated in Online Adaptive Radiotherapy Trial With CyberKnife System
News | Stereotactic Body Radiation Therapy (SBRT) | April 06, 2018
Accuray Inc. and Erasmus MC announced the first patient has been successfully treated using an online-adaptive (OA)...
Brainomix Secures $9.8m Investment to Tackle Strokes With AI
News | Stroke | April 05, 2018
April 5, 2018 — Medical imaging company Brainomix has attracted £7m ($9.8 million) of investment to bring its...
ASTRO Updates Guidelines for Palliative Lung Radiation Therapy
News | Radiation Therapy | April 05, 2018
The American Society for Radiation Oncology (ASTRO) issued an update to its clinical guideline for the use of...
FDA Clears Siemens Somatom Edge Plus CT System
Technology | Computed Tomography (CT) | April 04, 2018
April 4, 2018 — The U.S.
Overlay Init